EA201591977A1 - Противораковая терапия анти-egfr антителами, имеющими низкое фукозилирование - Google Patents
Противораковая терапия анти-egfr антителами, имеющими низкое фукозилированиеInfo
- Publication number
- EA201591977A1 EA201591977A1 EA201591977A EA201591977A EA201591977A1 EA 201591977 A1 EA201591977 A1 EA 201591977A1 EA 201591977 A EA201591977 A EA 201591977A EA 201591977 A EA201591977 A EA 201591977A EA 201591977 A1 EA201591977 A1 EA 201591977A1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- treatment
- antibodies
- foocosyling
- low
- egfr
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/40—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against enzymes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6871—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting an enzyme
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N5/00—Radiation therapy
- A61N5/10—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
- C07K2317/41—Glycosylation, sialylation, or fucosylation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biomedical Technology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Oncology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Pathology (AREA)
- Radiology & Medical Imaging (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP13002106 | 2013-04-22 | ||
| EP13002108 | 2013-04-22 | ||
| PCT/EP2014/058118 WO2014173886A1 (en) | 2013-04-22 | 2014-04-22 | Anti-cancer treatments with anti-egfr antibodies having a low fucosylation |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| EA201591977A1 true EA201591977A1 (ru) | 2016-06-30 |
Family
ID=50729450
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EA201591977A EA201591977A1 (ru) | 2013-04-22 | 2014-04-22 | Противораковая терапия анти-egfr антителами, имеющими низкое фукозилирование |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US20160068609A1 (https=) |
| EP (1) | EP2989126A1 (https=) |
| JP (1) | JP2016516800A (https=) |
| KR (1) | KR20150144804A (https=) |
| CN (1) | CN105229030A (https=) |
| AU (1) | AU2014257650A1 (https=) |
| BR (1) | BR112015025955A2 (https=) |
| CA (1) | CA2908819A1 (https=) |
| EA (1) | EA201591977A1 (https=) |
| MX (1) | MX2015014773A (https=) |
| SG (1) | SG11201507743XA (https=) |
| WO (1) | WO2014173886A1 (https=) |
| ZA (1) | ZA201507246B (https=) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10478498B2 (en) | 2014-06-20 | 2019-11-19 | Reform Biologics, Llc | Excipient compounds for biopolymer formulations |
| CN105820248A (zh) * | 2015-01-07 | 2016-08-03 | 上海张江生物技术有限公司 | 一种新型抗egfr单克隆抗体的制备方法及应用 |
| CN105399830B (zh) * | 2015-09-08 | 2019-11-19 | 北京天广实生物技术股份有限公司 | 抗egfr人源化单克隆抗体、其制备方法及用途 |
| US20170247458A1 (en) * | 2016-01-10 | 2017-08-31 | Sorrento Therapeutics, Inc. | Safety for Treating Cancers with a Glycosylated Chimeric Antibody to EGFR |
| SI3449939T1 (sl) | 2016-04-27 | 2022-06-30 | Green Cross Corporation | Farmacevtski sestavek za zaviranje metastaz pri raku, ki kot učinkovino obsega protitelo, ki se specifično veže na receptor za epidermalni rastni faktor |
| US11649291B2 (en) | 2016-05-24 | 2023-05-16 | Insmed Incorporated | Antibodies and methods of making same |
| WO2018013673A1 (en) * | 2016-07-13 | 2018-01-18 | Reform Biologics, Llc | Stabilizing excipients for therapeutic protein formulations |
| KR101884614B1 (ko) | 2016-10-11 | 2018-08-02 | 신일제약주식회사 | Fab 단편 및 이의 용도 |
| CN111315776A (zh) * | 2017-03-29 | 2020-06-19 | 葛莱高托普有限公司 | Pd-l1和ta-muc1抗体 |
| CN118267470A (zh) * | 2017-04-13 | 2024-07-02 | 赛罗帕私人有限公司 | 抗SIRPα抗体 |
| KR20200031571A (ko) * | 2017-05-29 | 2020-03-24 | 가마맵스 파마 | 암 연관 면역억제의 억제제 |
| US20210269530A1 (en) * | 2018-05-14 | 2021-09-02 | Harpoon Therapeutics, Inc. | Conditionally activated binding protein comprising a sterically occluded target binding domain |
| WO2020061482A1 (en) | 2018-09-21 | 2020-03-26 | Harpoon Therapeutics, Inc. | Egfr binding proteins and methods of use |
| JP7493237B2 (ja) * | 2018-11-14 | 2024-05-31 | 学校法人金沢医科大学 | びまん性胃がんを治療するための医薬組成物 |
| CN112300278A (zh) * | 2019-07-25 | 2021-02-02 | 上海交通大学 | 抗人egfr嵌合抗体及其制备方法和用途 |
| MX2022013182A (es) * | 2020-04-24 | 2023-01-16 | Merus Nv | Tratamiento de cánceres con un anticuerpo que se une a lgr5 y egfr. |
| CN115960214A (zh) * | 2021-10-12 | 2023-04-14 | 中国科学院分子细胞科学卓越创新中心 | 中和呼吸道合胞病毒的全人抗体的设计及应用 |
| EP4476263A4 (en) * | 2022-02-09 | 2026-01-28 | Dragonfly Therapeutics Inc | PHARMACEUTICAL FORMULATIONS AND THERAPEUTIC USES OF MULTI-SPECIFIC BINDING PROTEINS THAT BIND TO EGFR, NKG2D AND CD16 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HU230769B1 (hu) | 1999-01-15 | 2018-03-28 | Genentech Inc. | Módosított effektor-funkciójú polipeptid-változatok |
| EP1176195B1 (en) | 1999-04-09 | 2013-05-22 | Kyowa Hakko Kirin Co., Ltd. | Method for controlling the activity of immunologically functional molecule |
| EP2322644A1 (en) | 2000-06-28 | 2011-05-18 | GlycoFi, Inc. | Methods for producing modified glycoproteins |
| HUP0600342A3 (en) | 2001-10-25 | 2011-03-28 | Genentech Inc | Glycoprotein compositions |
| CA2481920A1 (en) | 2002-04-09 | 2003-10-16 | Kyowa Hakko Kogyo Co., Ltd. | Antibody composition-containing medicament |
| FR2858235B1 (fr) | 2003-07-31 | 2006-02-17 | Lab Francais Du Fractionnement | Utilisation d'anticorps optimises en adcc pour traiter les patients faibles repondeurs |
| AU2006211037B2 (en) * | 2005-02-07 | 2012-05-24 | Roche Glycart Ag | Antigen binding molecules that bind EGFR, vectors encoding same, and uses thereof |
| SI2073842T1 (sl) | 2006-09-10 | 2015-05-29 | Glycotope Gmbh | Uporaba človeških celic izvirajočih iz mieloične levkemije za izražanje protiteles |
| US20110200595A1 (en) * | 2010-02-18 | 2011-08-18 | Roche Glycart | TREATMENT WITH A HUMANIZED IgG CLASS ANTI EGFR ANTIBODY AND AN ANTIBODY AGAINST INSULIN LIKE GROWTH FACTOR 1 RECEPTOR |
| WO2012020065A1 (en) * | 2010-08-10 | 2012-02-16 | Glycotope Gmbh | Fab-glycosylated antibodies |
| EP2603527A1 (en) * | 2010-08-10 | 2013-06-19 | Glycotope GmbH | Humanized egfr antibodies |
-
2014
- 2014-04-22 US US14/784,470 patent/US20160068609A1/en not_active Abandoned
- 2014-04-22 CN CN201480021328.XA patent/CN105229030A/zh active Pending
- 2014-04-22 BR BR112015025955A patent/BR112015025955A2/pt not_active IP Right Cessation
- 2014-04-22 WO PCT/EP2014/058118 patent/WO2014173886A1/en not_active Ceased
- 2014-04-22 CA CA2908819A patent/CA2908819A1/en not_active Abandoned
- 2014-04-22 AU AU2014257650A patent/AU2014257650A1/en not_active Abandoned
- 2014-04-22 SG SG11201507743XA patent/SG11201507743XA/en unknown
- 2014-04-22 MX MX2015014773A patent/MX2015014773A/es unknown
- 2014-04-22 JP JP2016508192A patent/JP2016516800A/ja not_active Withdrawn
- 2014-04-22 EP EP14724007.1A patent/EP2989126A1/en not_active Withdrawn
- 2014-04-22 KR KR1020157033309A patent/KR20150144804A/ko not_active Withdrawn
- 2014-04-22 EA EA201591977A patent/EA201591977A1/ru unknown
-
2015
- 2015-09-30 ZA ZA2015/07246A patent/ZA201507246B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CA2908819A1 (en) | 2014-10-30 |
| SG11201507743XA (en) | 2015-11-27 |
| JP2016516800A (ja) | 2016-06-09 |
| KR20150144804A (ko) | 2015-12-28 |
| US20160068609A1 (en) | 2016-03-10 |
| BR112015025955A2 (pt) | 2017-10-17 |
| MX2015014773A (es) | 2016-03-04 |
| CN105229030A (zh) | 2016-01-06 |
| ZA201507246B (en) | 2016-12-21 |
| WO2014173886A1 (en) | 2014-10-30 |
| EP2989126A1 (en) | 2016-03-02 |
| AU2014257650A1 (en) | 2015-11-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EA201591977A1 (ru) | Противораковая терапия анти-egfr антителами, имеющими низкое фукозилирование | |
| EA201992251A1 (ru) | Противораковые вакцины и способы лечения с их применением | |
| WO2013177187A3 (en) | Synergistic tumor treatment with extended-pk il-2 and therapeutic agents | |
| MX2018014175A (es) | Conjugados de anticuerpo-fármaco anti-cmet y métodos para su uso. | |
| PH12016501139B1 (en) | Bicyclic heterocycle compounds and their uses in therapy | |
| PT2958945T (pt) | Terapia de combinação envolvendo anticorpos contra claudina 18.2 para tratamento de cancro | |
| EA201790932A1 (ru) | Дозировка и введение нефукозилированных анти-cd40 антител | |
| EA201591616A1 (ru) | Трифторметил-замещенные аннелированные пиримидины и их применение | |
| EA201590987A1 (ru) | Соединения и способы их применения | |
| EA201590997A1 (ru) | Соединения и способы их применения | |
| HK1221424A1 (zh) | 治疗癌症的药物组合 | |
| GEP20217317B (en) | Combination therapy for the treatment of cancer | |
| MX384751B (es) | Tratamiento del cáncer con una combinación de plinabulina y taxano. | |
| MX2015011783A (es) | Metodos para tratar tumores solidos pediatricos. | |
| EA201591925A1 (ru) | Терапевтические композиции и их применение | |
| MX379271B (es) | Compuestos desestabilizadores de microtubulina para usarse en el tratamiento del cáncer. | |
| MX2016007445A (es) | Inhibidores de f1f0-atpasa de trifluorometil pirazolil guanidina y usos terapeuticos de los mismos. | |
| HK1250626A1 (zh) | 借助塞里班土单抗的组合治疗 | |
| ZA201708686B (en) | Nanoparticles for use as a therapeutic vaccine | |
| AU2018253600A1 (en) | Dosage forms and therapeutic uses of l-4-chlorokynurenine | |
| EA201791814A1 (ru) | Имидазолильные трициклические еноны как антиоксидантные модуляторы воспаления | |
| NZ701974A (en) | Novel therapeutic treatments with anti-her2 antibodies having a low fucosylation | |
| EA201791819A1 (ru) | Комбинированная терапия с применением конъюгата антитела против cd19 с лекарственным средством и винкристина | |
| EA201690445A1 (ru) | Лечение рака | |
| MX2017013668A (es) | Terapia de combinacion de agente anti-fuctactico y agente anti-cancer y composiciones para el tratamiento de cancer. |